Comprehensive pathogen profiling Aperiomics offers broad infectious disease identification by sequencing all known bacteria, virus, fungus, and parasite types using Deep Shotgun Metagenomic Sequencing, supported by a large microbial database. This presents an opportunity to upsell to hospitals and clinics seeking comprehensive diagnostic capabilities beyond targeted tests.

Clinical outcomes focus Their technology is positioned to identify elusive infection causes, accelerating time to diagnosis and positive clinical outcomes. Sales potential exists with health systems aiming to reduce prolonged investigations, readmission rates, or long-standing patient sickness with unclear etiologies.

Strategic partnerships Recent collaborations with Janelia Research Campus, Antibody Biopharm, IDT, and Zymo indicate a readiness to co-develop and scale tests. This suggests openings for co-marketing deals, integration partnerships, or preferred vendor arrangements with biotech suppliers and research institutions.

Public recognition Industry awards and NSF support bolster credibility for procurement discussions. Leverage Life Science Innovator of the Year and International Start Up of the Year recognitions when engaging with procurement teams to facilitate budget conversations and stakeholder buy-in.

Growth readiness With a mid-sized team and revenue in the low-to-mid seven figures, Aperiomics appears poised for scale. Focus on enterprise contracts, managed services, and lab capacity expansion opportunities with mid to large health networks seeking scalable genomic testing capabilities.